CCMI
AIM

Creative Capital Management Investments’s AIM ImmunoTech AIM Stock Holding History

Creative Capital Management Investments’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2
Closed -$86 – 251
2023
Q1 		$86 Hold
2
– – ﹤0.01% 237
2022
Q4 		$0 Buy
+2
New +$93 ﹤0.01% 233

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Creative Capital Management Investments's AIM Position: Q2 2023 in Review

Creative Capital Management Investments sold out of AIM ImmunoTech (AIM) in Q2 2023, closing a stake of 2 shares — an estimated $86 sold.

Creative Capital Management Investments first reported a position in AIM in Q4 2022 and held it in 2 quarters. The position peaked at $86 in Q1 2023. 30 funds tracked by Wall St. Rank hold AIM as of Q2 2023.

  • Creative Capital Management Investments reported no remaining AIM ImmunoTech position as of Q2 2023 after selling out during the quarter.
  • Creative Capital Management Investments sold 2 AIM ImmunoTech shares in Q2 2023, an estimated $86.
  • Creative Capital Management Investments first reported a position in AIM ImmunoTech in Q4 2022 and held it in 2 quarters.
  • Creative Capital Management Investments's AIM ImmunoTech position peaked at $86 in Q1 2023.
  • 30 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2023.

Based on Creative Capital Management Investments's 13F filing for Q2 2023, filed 25 Jul 2023.